Market Research Logo

Global Central Nervous System (CNS) Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022

1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. MARKET DEFINITION AND SCOPE
2.2. KEY FINDINGS
2.3. PARAMETRIC ANALYSIS
2.3.1. PREVALENCE & INCIDENCE RATE OF ALZHEIMER’S DISEASE
2.3.2. HOSPITAL AND RESEARCH CENTER ACROSS GEOGRAPHIES
2.3.3. PREVALENCE & INCIDENCE RATE OF PARKINSON’S DISEASE
2.3.4. PREVALENCE & INCIDENCE RATE OF CANCER DISEASE
2.3.5. HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
2.4. KEY MARKET INSIGHTS
2.4.1. TOP 3 EMERGING COUNTRIES
2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
2.4.4. TOP 3 GEOGRAPHY
2.5. COMPETITIVE LANDSCAPE
2.5.1. MARKET SHARE ANALYSIS
2.5.2. TOP WINNING STRATEGIES
2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
2.6. PORTER’S FIVE FORCE MODEL
2.6.1. THREAT OF NEW ENTRANTS
2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
2.6.3. BARGAINING POWER OF BUYER
2.6.4. BARGAINING POWER OF SUPPLIER
2.6.5. INTENSITY OF COMPETITIVE RIVALRY
2.7. KEY BUYING CRITERIA
2.8. STRATEGIC RECOMMENDATION
2.9. STRATEGIC CONCLUSIONS
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. DEVELOPMENT IN PROTEOMICS, GENOMICS AND IMAGING SYSTEM HAS INCREASED DEMAND FOR CNS BIOMARKER.
3.1.2. FUNDING FROM GOVERNMENT AND PRIVATE PLAYERS TO BOOST CNS BIOMARKER MARKET
3.1.3. GROWTH IN LIFE STYLE ORIENTED DISEASES
3.1.4. GROWTH IN GOVERNMENT AND PRIVATE FUNDING IN CNS BIOMARKER MARKET
3.1.5. GROWTH IN PUBLIC-PRIVATE PARTNERSHIP
3.1.6. FDA APPROVALS GIVING RISE TO SIGNIFICANT SCOPE IN BIOMARKER MARKET
3.1.7. TECHNOLOGICAL ADVANCEMENT ENABLES TO EXPAND CNS BIOMARKER MARKET
3.1.8. INNOVATION GIVING RISE TO GROWTH OF CNS BIOMARKER MARKET
3.1.9. GLOBAL INCREASE IN HEALTHCARE EXPENDITURE
3.2. MARKET RESTRAINTS
3.2.1. HIGH COST OF CNS BIOMARKER TEST AND DIAGNOSTICS
3.2.2. REIMBURSEMENT ISSUES AFFECTING THE CNS BIOMARKER MARKET
3.3. MARKET OPPORTUNITIES
3.3.1. INCREASING ADOPTION OF PERSONALIZED MEDICINES
3.3.2. UNTAPPED APAC REGION HAS HUGE SCOPE FOR CNS BIOMARKER MARKET
3.3.3. GLOBAL INCREASE IN AGING POPULATION HAS CREATED HUGE SCOPE FOR CNS BIOMARKER MARKET
3.3.4. FAVORABLE GOVERNMENT POLICIES AND SUPPORT FOR CNS BIOMARKERS
3.4. MARKET CHALLENGES
3.4.1. CREATING AWARENESS FOR CNS BIOMARKER MARKET
3.4.2. GLOBAL ECONOMIC SLOWDOWN MAY AFFECT THE CNS BIOMARKER MARKET
3.4.3. TECHNICAL ISSUES OF SAMPLE COLLECTION AND STORAGE
3.5. PARENT MARKET
3.6. COMPETITORS MARKET
3.7. ALTERNATIVE MARKET
4. MARKET SEGMENTATION
4.1. GLOBAL CNS BIOMARKER MARKET BY APPLICATION, 2014-2022,($ MILLIONS)
4.1.1. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
4.1.2. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
4.1.3. GLOBAL PERSONALIZED MEDICINE MARKET, 2014-2022,($ MILLIONS)
4.1.4. GLOBAL DISEASE RISK ASSESSMENT MARKET, 2014-2022,($ MILLIONS)
4.1.5. GLOBAL OTHER MARKET , 2014-2022,($ MILLIONS)
4.2. GLOBAL CNS BIOMARKER MARKET BY TYPE, 2014-2022,($ MILLIONS)
4.2.1. GLOBAL SAFETY BIOMARKER MARKET , 2014-2022,($ MILLIONS)
4.2.2. GLOBAL EFFICACY BIOMARKER MARKET, 2014-2022,($ MILLIONS
4.2.3. GLOBAL PREDICTIVE BIOMARKER MARKET, 2014-2022,($ MILLIONS)
4.2.4. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
4.2.5. GLOBAL PROGNOSTIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
4.2.6. GLOBAL VALIDATION BIOMARKER MARKET, 2014-2022,($ MILLIONS)
4.3. GLOBAL CNS BIOMARKER MARKET BY END USERS, 2014-2022,($ MILLIONS)
4.3.1. GLOBAL CNS BIOMARKER MARKET BY HOSPITALS, 2014-2022,($MILLIONS)
4.3.2. GLOBAL CNS BIOMARKER MARKET BY EYE CLINICS, 2014-2022,($MILLIONS)
4.3.3. GLOBAL CNS BIOMARKER MARKET BY DIAGNOSTIC CENTERS, 2014-2022,($MILLIONS)
4.3.4. GLOBAL CNS BIOMARKER MARKET BY PATIENTS, 2014-2022,($MILLIONS)
5. GEOGRAPHICAL ANALYSIS
5.1. NORTH AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.1.1. UNITED STATES (U.S.) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.1.2. CANADA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.2. EUROPE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.2.1. UNITED KINGDOM (UK) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.2.2. FRANCE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.2.3. GERMANY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.2.4. SPAIN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.2.5. ITALY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.2.6. ROE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.3. ASIA PACIFIC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.3.1. INDIA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.3.2. CHINA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.3.3. JAPAN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.3.4. ROAPAC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.4. REST OF THE WORLD CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.4.1. LATIN AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.4.2. MENA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
5.4.3. AFRICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
6. COMPANY PROFILING: - (OVER, SCOT ANALYSIS, STRATEGIC REVIEW)
1. ABASTAR MDX INC
2. ABIANT INC
3. ACUMEN PHARMACEUTICALS INC
4. ADLYFE INC
5. ALSERES PHARMACEUTICALS INC
6. APITOPE INTERNATIONAL
7. APOSENSE
8. APPLIED NEUROSOLUTIONS INC
9. AVACTA GROUP PLC
10. AVID RADIOPHARMACEUTICALS INC
11. BANYAN BIOMARKERS
12. DIAGENIC ASA
13. EKFDIAGNOSTICS HOLDINGS INC
14. ENZO BIOCHEM INC
15. EXONHIT THERAPEUTICS
16. GENENEWS LTD
17. GLYCOMINDS LTD
18. GREAT LAKES NEUROTECHNOLOGIES
19. INNOGENETICS BIOLOGICALS
20. INNOVATIVE NEUROTECHNOLOGIES INC
21. MERC & CO. IN
22. METABOLON INC
23. MYRIAD RBM INC
24. OLIGOMERIX INC
25. OPKO HEALTH INC
26. OSTA BIOTECHNOLOGIES INC
27. PROTEOME SCIENCES PRODUCTS
28. PSYNOVA NEUROTECH LTD
29. RIDGE DIAGNOSTICS
30. SABIOSCIENCES
31. SATORI PHARMACEUTICAL INC
32. THERMO FISHER SCIENTIFIC
List of Tables
1. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
2. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
3. GLOBAL PERSONALIZED MEDICINE MARKET, 2014-2022,($ MILLIONS)
4. GLOBAL DISEASE RISK ASSESSMENT MARKET, 2014-2022,($ MILLIONS)
5. GLOBAL OTHER MARKET , 2014-2022,($ MILLIONS)
6. GLOBAL SAFETY BIOMARKER MARKET , 2014-2022,($ MILLIONS)
7. GLOBAL EFFICACY BIOMARKER MARKET, 2014-2022,($ MILLIONS
8. GLOBAL PREDICTIVE BIOMARKER MARKET, 2014-2022,($ MILLIONS)
9. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
10. GLOBAL PROGNOSTIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
11. GLOBAL VALIDATION BIOMARKER MARKET, 2014-2022,($ MILLIONS)
12. GLOBAL CNS BIOMARKER MARKET BY HOSPITALS, 2014-2022,($MILLIONS)
13. GLOBAL CNS BIOMARKER MARKET BY EYE CLINICS, 2014-2022,($MILLIONS)
14. GLOBAL CNS BIOMARKER MARKET BY DIAGNOSTIC CENTERS, 2014-2022,($MILLIONS)
15. GLOBAL CNS BIOMARKER MARKET BY PATIENTS, 2014-2022,($MILLIONS)
16. NORTH AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
17. UNITED STATES (U.S.) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
18. CANADA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
19. EUROPE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
20. UNITED KINGDOM (UK) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
21. FRANCE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
22. GERMANY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
23. SPAIN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
24. ITALY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
25. ROE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
26. ASIA PACIFIC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
27. INDIA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
28. CHINA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
29. JAPAN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
30. ROAPAC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
31. REST OF THE WORLD CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
32. LATIN AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
33. MENA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
34. AFRICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
List of Figures
1. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
2. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
3. GLOBAL PERSONALIZED MEDICINE MARKET, 2014-2022,($ MILLIONS)
4. GLOBAL DISEASE RISK ASSESSMENT MARKET, 2014-2022,($ MILLIONS)
5. GLOBAL OTHER MARKET , 2014-2022,($ MILLIONS)
6. GLOBAL SAFETY BIOMARKER MARKET , 2014-2022,($ MILLIONS)
7. GLOBAL EFFICACY BIOMARKER MARKET, 2014-2022,($ MILLIONS
8. GLOBAL PREDICTIVE BIOMARKER MARKET, 2014-2022,($ MILLIONS)
9. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
10. GLOBAL PROGNOSTIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
11. GLOBAL VALIDATION BIOMARKER MARKET, 2014-2022,($ MILLIONS)
12. GLOBAL CNS BIOMARKER MARKET BY HOSPITALS, 2014-2022,($MILLIONS)
13. GLOBAL CNS BIOMARKER MARKET BY EYE CLINICS, 2014-2022,($MILLIONS)
14. GLOBAL CNS BIOMARKER MARKET BY DIAGNOSTIC CENTERS, 2014-2022,($MILLIONS)
15. GLOBAL CNS BIOMARKER MARKET BY PATIENTS, 2014-2022,($MILLIONS)
16. NORTH AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
17. UNITED STATES (U.S.) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
18. CANADA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
19. EUROPE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
20. UNITED KINGDOM (UK) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
21. FRANCE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
22. GERMANY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
23. SPAIN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
24. ITALY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
25. ROE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
26. ASIA PACIFIC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
27. INDIA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
28. CHINA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
29. JAPAN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
30. ROAPAC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
31. REST OF THE WORLD CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
32. LATIN AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
33. MENA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
34. AFRICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)

Global Central Nervous System (CNS) Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022

A biomarker is a biological feature that are used to measure the biological state, presence of diseases or progress of effects of treatment. It helps in understanding various chronic diseases, its effects on exposure to certain environmental conditions and also in identification of people who are at high risk of developing the same disease being diagnosed. The demand for CNS biomarker has increased with the development of in proteomics, genomics and imaging system, which is a major drivers of the Global Central Nervous System Biomarkers Market. The global CNS biomarker market is witnessing a moderate to high growth in the recent years and is expected to continue so on in the near future. The global CNS biomarker market is expected to reach up to $ 6.2 billion by 2022 growing at 10.4% CAGR during 2016-2022.

The major factors identified that are driving the CNS biomarker market are support from private players and government for increased research and development, development of genomics and imaging system, rapidly increasing aging population and increased public private partnerships. Recently, FDA has approved use CNS biomarkers which has led to its significant growth in the North American region. The world is experiencing a significant growth in aging population. As per Administration for Community Living, population aged 65 and above is estimated to reach more than 80 million by 2050, which is twice of that estimated in 2012.This growth in aging population is leading to increased development of many CNS disorders like Parkinson’s, Alzheimer’s disease and multiple sclerosis. As per the Aging Research Center, approximately 24 million people are affected with Alzheimer’s disease globally. Governments are supporting and funding private and public laboratories to overcome this research and development program across the country. In addition, technological advancements and innovations, development of new applications areas, increasing lifestyle oriented diseases etc. are few factors which are likely to spur the demand of global CNS biomarker market. . Nevertheless, the increasing demand of personalized medicines, large untapped market in emerging economies of APAC and favorable government policies are the few opportunities area for the global CNS biomarker market.

The Global Central Nervous System Biomarkers market is segmented on the basis of type, applications and end users. On the basis of type the market is segmented safety biomarker, efficacy biomarker, predictive biomarker, pharmacodynamic biomarker, prognostic biomarker and validation biomarker. On the basis of application it is segmented as diagnostic development, drug discovery and development, personalized medicine market, disease risk assessment market and other market. In the application segment personalized medicine market is expected to have a significant growth due to its increasing demand by patients. The end-use industry segments comprise the Hospitals, eye clinics, diagnostic centers and patients. The major regional segments analyzed in the report include North America, Europe, Asia Pacific, and Rest of the World with further bifurcation of them on country level, which includes U.S, Canada, India, China, Japan, Germany, U.K., Spain, Brazil etc. Asia Pacific is anticipated to be one the fastest growing market in the global CNS biomarker market. The major reason for high growth is wide customer base in the region, improving healthcare infrastructure, purchasing power of buyers and increasing government initiatives. However at present, North America has the largest market share in global CNS biomarker marker because in the region healthcare infrastructure is more advanced than any other and also because of increasing ageing population. For instance, according to the U.S. Census Bureau approximately 20% of the U.S. population is projected to be 65 years and above by 2030.Some of the key market players are Abiant Inc., Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Apitope International, Aposense, Avacta Group Plc, Banyan Biomarkers, Diagenic ASA, EKFDiagnostics Holdings Inc., Enzo Biochem Inc., Exonhit Therapeutics, Genenews Ltd, Great Lakes Neuro Technologies, Innogenetics Biological, Innovative Neuro Technologies Inc., Metabolon Inc., Myriad RBM Inc., Oligomerix Inc., Opko Health Inc., Proteome Sciences Products, Psynova Neurotech Ltd, Ridge Diagnostics, Sabiosciences, Satori Pharmaceutical Inc. And Thermo Fisher Scientific. Expansions, Mergers & acquisition and collaborations for product development are the key strategies adopted by the market players to sustain in the market also companies are applying for patents for any new product they develop. In January 2016, D Banyan Biomarkers into an agreement to develop and commercialize hand held blood test to evaluate and detect concussions. With this collaboration Banyan Biomarkers will be able utilize its knowledge of bio molecules responsible for neurological injuries and take an advantage of Philips’ strength in handheld diagnostic and patient monitoring technologies. Similarly in February 2014, in a deal of $270 million cash Myriad genetics acquired Crescendo Bioscience. By this acquisition Myriad will be able to use Crescendo Bioscience’s Vectra DA test which is used to measure level of disease activity in a patient suffering from rheumatoid arthritis.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


Companies Mentioned

1. ABASTAR MDX INC
2. ABIANT INC
3. ACUMEN PHARMACEUTICALS INC
4. ADLYFE INC
5. ALSERES PHARMACEUTICALS INC
6. APITOPE INTERNATIONAL
7. APOSENSE
8. APPLIED NEUROSOLUTIONS INC
9. AVACTA GROUP PLC
10. AVID RADIOPHARMACEUTICALS INC
11. BANYAN BIOMARKERS
12. DIAGENIC ASA
13. EKFDIAGNOSTICS HOLDINGS INC
14. ENZO BIOCHEM INC
15. EXONHIT THERAPEUTICS
16. GENENEWS LTD
17. GLYCOMINDS LTD
18. GREAT LAKES NEUROTECHNOLOGIES
19. INNOGENETICS BIOLOGICALS
20. INNOVATIVE NEUROTECHNOLOGIES INC
21. MERC & CO. IN
22. METABOLON INC
23. MYRIAD RBM INC
24. OLIGOMERIX INC
25. OPKO HEALTH INC
26. OSTA BIOTECHNOLOGIES INC
27. PROTEOME SCIENCES PRODUCTS
28. PSYNOVA NEUROTECH LTD
29. RIDGE DIAGNOSTICS
30. SABIOSCIENCES
31. SATORI PHARMACEUTICAL INC
32. THERMO FISHER SCIENTIFIC

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;